To learn about our parent company, Takeda Pharmaceutical Company Limited, please visit http://www.takeda.com/
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
Takeda Launches CDPATH™, a Personalized Prognostic Tool, Advancing Innovation for Patients with Crohn’s Disease
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
Takeda’s TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States
Takeda Receives U.S. FDA Approval for Prefilled Syringe Presentation of TAKHZYRO® (lanadelumab-flyo) for Use as a Preventive Treatment for Hereditary Angioedema Attacks
SEE ALL NEWS AND RELEASES >
Copyright 2022 Takeda Pharmaceutical Company Limited. All rights reserved.Certified Top Employer
You are about to leave www.Takeda.com/en-us and be redirected to another Takeda domain.